all report title image
  • To Be Published : Nov 2023
  • Code : CMI554
  • Pages : N/A
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Cushing’s syndrome is a collection of symptoms and signs, which includes high blood pressure, reddish stretch marks, abdominal obesity, round red face, weak muscles, weak bones, a fat lump between the shoulders and fragile skin that heals slowly due to prolonged exposure to cortisol. Excessive cortisol-like medication such as prednisone or tumor that is produced due to excess cortisol by adrenal glands are the two basic factors that cause Cushing’s syndrome. Other tumors may also cause this disease, which are associated with inherited disorders such as multiple endocrine neoplasia type 1 and Carney complex. Most cases can be treated and cured by combination of surgery radiation or chemotherapy.

The most significant cause of Cushing’s syndrome is intake of glucocorticoids prescribed by a healthcare professional to cure other diseases such as asthma, rheumatoid arthritis or in immunosuppression after an organ transplant. Administration of synthetic ACTH can also lead to the condition. It may also occur in other animals such as cats, dogs, and horse. All the factors mentioned above are expected to favor the growth of Cushing’s syndrome market.

Hormonal disorder caused due to prolonged exposure of body’s tissue to high levels of hormone cortisol leads to Cushing’s syndrome, also called hypercortisolism. Adults aged in the age group of 20-50 years suffer from Cushing’s syndrome. It is rarely seen, though has risk of development in patient who are obese and also have type 2 diabetes, high blood pressure with poorly controlled blood glucose. Cushing’s syndrome market is projected to increase due to rise in its awareness and healthcare expenditure. Various new drugs are available in market due to increase in research and development such as ketoconazole, metyrapone and mitotane to minimize the surgical risk of patient. According to Orphanet Journal of Rare Disease, incidence of Cushing’s syndrome is estimated to be equal to 1–3 cases per million inhabitants per year, whereas its prevalence is close to 40 cases per million inhabitants in 2012.

Cushing’s Syndrome Market- Regional Analysis

In terms of geography Cushing’s syndrome is segmented into North America, Europe, Asia-pacific, Middle East, Latin America and Africa. Due to presence of high income standard and health awareness in North America favors the growth of Cushing’s syndrome market. According to Centers for Disease Control and Prevention more than one-third of the U.S. adults have obesity which is a leading cause to Cushing’s syndrome that was 36.5% during 2011-2014. Furthermore, according to American Diabetes Association type 2 diabetes is most commonly seen in African Americans, Latin Americans and Asia Pacific Islanders.

Cushing’s Syndrome Market- Competitive Landscape

Increase in research and development in 2016, which includes development of clinical trials for RECORLEV for the treatment of endogenous Cushing’s syndrome by Strongbrigde Biopharma plc is expected to create competition and also favor the growth between various manufacture to lead the market. The key players operating in Cushing’s syndrome market include Corcept Therapeutics Inc., HRA Pharma, Strongbridge Biopharma plc., and Novartis AG.

 Key Development

  • In November 2019, osilodrostat, which is used for the treatment of patient with Cushing syndrome in adults, had got positive opinion by The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).Furthermore, on 6th March 2020, Isturisa (osilodrostat), has been approved by U.S Food and Drug Administration 9FDA). Isturisa (osilodrostat) is an oral tablet used in the patient who cannot go for pituitary gland surgery or has not been curative.
  • In September 2019, positive result from the phase 3 clinical trial for RECORLEV (levoketoconazole) drug had been announced by Strongbridge Biopharma plc Company. RECORLEV (levoketoconazole) drug is used for the treatment of endogenous Cushing’s syndrome.
  • In June 2018, pasireotide drug (Signifor, Novartis), which is used for the treatment of patient with Cushing syndrome who cannot go for pituitary gland surgery or has not been curative., had been approved by U.S Food and Drug Administration (FDA).

Cushing’s syndrome Market- taxonomy

The global Cushing’s syndrome market is segmented on the basis of drug type, end user and region.

By Drug Type

  • Etomidate
  • Ketoconazole
  • Pasireotide
  • Aminoglutethimide
  • Mitotane
  • Metyrapone
  • Mifepristone

 By End User

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Clinics
  • Drug Stores
  • E-Commerce/Online Pharmacy

 By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo